by Carl Noe, M.D., Anesthesiology & Pain Management, UT Southwestern Medical Center, Dallas, TX; and Eugene McDermott Center for Pain Management, Dallas, Texas Dr. Noe is the Principal Investigator in the ongoing trial of SP-SAP Intrathecal SP-SAP (Substance P attached to the ribosome-inactivating protein, saporin) has been studied in a Phase 1 clinical trial of […]
Custom Biotinylation, when the “one-step-kit” doesn’t quite meet your needs. Proteins come in all shapes and sizes and don’t always contain a ready-to-conjugate binding site. This and other variables can cause you to look toward one-step kits, often leaving you with un-purified and un-verified conjugate. Let the experts in the field help provide you with
Targeting Tools: Custom Biotinylation Service Read More »
by Masahiro Sato1 (Ph. D.) and Satoshi Watanabe2 (Ph. D.) 1Section of Gene Expression Regulation, Frontier Science Research Center, Kagoshima University, Kagoshima 890-8544, Japan: 2Animal Genome Research Unit, Division of Animal Science, National Institute of Agrobiological Sciences, Ibaraki 305-8602, Japan Isolation of stable transfectants is one of the important steps for exploring biological functions of
The ZAP Sulforhodamine B (SrB; Cat. #KIT-SrB-Z) Development kit contains all of the materials needed to introduce a quantitative staining assay to your lab. Preferred by the National Cancer Institute for high-throughput drug screening, SrB quantitatively stains cellular proteins in an accurate and reproducible manner. Refined and honed over years of use in testing Saporin-conjugate
Targeting Tools: ZAP SrB Development Kit Read More »
A groundbreaking pain therapeutic is poised for conditional approval in 2015 to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon
Veterinary Development of Substance P-Saporin (SP-SAP) Read More »
Congratulations to Dr. Kucinski as this year’s winner of the SfN Poster of the Year Award for the most interesting work presented using ATS products. You can read a summary of this work from Dr. Sarter’s lab in the cover article in this issue of Targeting Trends. Here is a small sample of the comments
Targeting Article: Society for Neuroscience Poster of the Year Award Read More »
by Aaron Kucinski (Collaborators at University Michigan, Ann Arbor: K. Phillips, R. Albin, M. Sarter) In addition to the primary disease-defining symptoms that result from extensive loss of nigrostriatal dopaminergic neurons, approximately half of patients with Parkinson’s Disease (PD) suffer from postural instability, impairments in gait control and a propensity for falls. These symptoms have
Read the 2014 Newsletters and recent scientific references 2014, issue 1: 2014, issue 2: 2014, issue 3: 2014, issue 4:
Targeting Trends 2014 Newsletter Read More »